LifeStance Health Group, Inc. (NASDAQ:LFST) Receives $9.00 Average Price Target from Brokerages

by · The Markets Daily

Shares of LifeStance Health Group, Inc. (NASDAQ:LFST – Get Free Report) have received an average recommendation of “Moderate Buy” from the nine research firms that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, one has given a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $9.00.

A number of brokerages have recently commented on LFST. Wall Street Zen raised LifeStance Health Group from a “hold” rating to a “buy” rating in a research note on Sunday, February 8th. Zacks Research lowered shares of LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 5th. BMO Capital Markets started coverage on shares of LifeStance Health Group in a research report on Thursday, November 13th. They set an “outperform” rating and a $8.00 target price on the stock. BTIG Research upped their price target on shares of LifeStance Health Group from $10.00 to $11.00 and gave the company a “buy” rating in a research report on Monday, February 2nd. Finally, UBS Group raised their price target on shares of LifeStance Health Group from $9.00 to $10.00 and gave the company a “buy” rating in a research note on Friday, November 7th.

Read Our Latest Stock Report on LFST

LifeStance Health Group Trading Up 0.7%

NASDAQ LFST opened at $7.14 on Friday. The company has a market cap of $2.78 billion, a price-to-earnings ratio of -238.00 and a beta of 1.12. LifeStance Health Group has a twelve month low of $3.74 and a twelve month high of $8.30. The company has a quick ratio of 1.58, a current ratio of 1.58 and a debt-to-equity ratio of 0.18. The business’s fifty day moving average is $7.11 and its 200 day moving average is $6.17.

Insiders Place Their Bets

In related news, insider Ann Varanakis sold 50,000 shares of LifeStance Health Group stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $6.90, for a total transaction of $345,000.00. Following the completion of the transaction, the insider owned 315,610 shares of the company’s stock, valued at $2,177,709. This trade represents a 13.68% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Robert Bessler sold 119,942 shares of the business’s stock in a transaction on Friday, December 19th. The shares were sold at an average price of $7.04, for a total transaction of $844,391.68. Following the completion of the transaction, the director owned 1,318,983 shares in the company, valued at approximately $9,285,640.32. The trade was a 8.34% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 270,086 shares of company stock valued at $1,891,264 over the last 90 days. 6.60% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of LFST. Invesco Ltd. grew its position in LifeStance Health Group by 6.9% in the 4th quarter. Invesco Ltd. now owns 205,486 shares of the company’s stock valued at $1,447,000 after purchasing an additional 13,177 shares during the period. Vident Advisory LLC lifted its stake in shares of LifeStance Health Group by 148.8% in the fourth quarter. Vident Advisory LLC now owns 37,462 shares of the company’s stock valued at $264,000 after buying an additional 22,406 shares in the last quarter. XTX Topco Ltd acquired a new position in shares of LifeStance Health Group during the fourth quarter valued at about $96,000. Zacks Investment Management increased its position in shares of LifeStance Health Group by 33.1% during the fourth quarter. Zacks Investment Management now owns 45,291 shares of the company’s stock worth $319,000 after acquiring an additional 11,270 shares in the last quarter. Finally, Janus Henderson Group PLC lifted its position in LifeStance Health Group by 58.8% in the 4th quarter. Janus Henderson Group PLC now owns 94,500 shares of the company’s stock valued at $666,000 after acquiring an additional 35,000 shares in the last quarter. 85.50% of the stock is owned by institutional investors.

About LifeStance Health Group

(Get Free Report)

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.

Read More